EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Comparative Effectiveness of Biofeedback vs Dextranomer–Hyaluronate Injection for Fecal Incontinence: A Randomized Clinical Trial

Adil E Bharucha, Satish S C Rao, William E Whitehead, Isuzu Meyer, William D Chey, Marie G Gantz, Holly E Richter, Heidi K Chua, Steven Heymen, Thanh T Lu, Stacy B Menees, William R G Perry und 4 weitere

Clinical Gastroenterology and Hepatology · 2026-10

DOI: 10.1016/j.cgh.2026.09.040 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10. Verfasst von Adil E Bharucha und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: bharucha.adil@mayo.edu. Die Arbeit nennt 37 Literaturangaben. Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Anal dextranomer injection and anorectal biofeedback therapy have not been rigorously compared in patients with fecal incontinence (FI) that is refractory to medical and behavioral therapy (MBT). This study compared their effectiveness, safety, and costs. METHODS: The Fecal Incontinence Treatment (FIT) study was a clinical trial conducted at 5 United States medical centers. Adults with MBT-unresponsive FI (≥4 episodes per 2 weeks) were randomized to receive either injections or biofeedback. The 3 outcomes were a ≥75% reduction in FI episodes at 3 months vs baseline; the proportion of patients with pelvic pain (grade ≥II), treatment-site infection, or serious adverse events (AEs) requiring hospitalization within 3 months of randomization; and treatment cost. RESULTS: Of 8705 screened participants, 275 began MBT and 267 completed it. Among MBT nonresponders, 200 patients (176 [88%] women, 34 [12%] men) were randomized to injections (n = 101) or biofeedback (n = 99). After 3 months, FI frequency decreased by ≥75% for similar proportions of each treatment arm (injection, n = 28/101 [27.7%] vs biofeedback, n = 29/99 [29.3%]; adjusted odds ratio, 0.9; 95% confidence interval [CI], 0.5-1.7; P = .79). Seven participants (injection, n = 5; biofeedback, n = 2; P = .27) had 11 relevant AEs, of which 5 were serious, nontreatment-related AEs (injection, n = 3; biofeedback, n = 2). Compared with biofeedback, injections cost an average of $1563 (95% CI, $1477-$1649) more per patient for payers (P < .001), $38 (95% CI, -$2 to $78) more for patients (P = .06), and $1579 (95% CI, $1464-$1694) more for society (P < .001). CONCLUSIONS: In this superiority trial, neither biofeedback nor dextranomer was superior for the primary efficacy endpoint in patients with moderate-to-severe, MBT-refractory FI. Biofeedback is less expensive for payers and society. CLINICALTRIALS: gov, Number: NCT03811821.

Schlagwörter

Stichwörter der Autor:innen

Anal IncontinenceCost EffectivePhysical TherapySacral Nerve Stimulation

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota. Electronic address: bharucha.adil@mayo.edu.
  • Division of Gastroenterology and Hepatology, Augusta University, Augusta, Georgia.
  • Division of Gastroenterology, UNC School of Medicine, University of North Carolina, Chapel Hill, North Carolina.
  • Department of Obstetrics and Gynecology, The University of Alabama at Birmingham, Birmingham, Alabama.
  • Department of Gastroenterology, University of Michigan Health, Brighton, Michigan.
  • RTI International, Research Triangle Park, North Carolina.

Förderung

  • NIDDK NIH HHS
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Bharucha, A. E., Rao, S. S. C., Whitehead, W. E., Meyer, I., Chey, W. D., Gantz, M. G., Richter, H. E., Chua, H. K., Heymen, S., Lu, T. T., Menees, S. B., Perry, W. R. G., Sridhar, A., Szarka, L. A., Busby-Whitehead, J., & Hamilton, F. A. (2026). Comparative Effectiveness of Biofeedback vs Dextranomer–Hyaluronate Injection for Fecal Incontinence: A Randomized Clinical Trial. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.09.040

Vancouver

Bharucha AE, Rao SSC, Whitehead WE, Meyer I, Chey WD, Gantz MG, et al. Comparative Effectiveness of Biofeedback vs Dextranomer–Hyaluronate Injection for Fecal Incontinence: A Randomized Clinical Trial. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.09.040

BibTeX
@article{Bharucha2026,
  author = {Bharucha, Adil E and Rao, Satish S C and Whitehead, William E and Meyer, Isuzu and Chey, William D and Gantz, Marie G and Richter, Holly E and Chua, Heidi K and Heymen, Steven and Lu, Thanh T and Menees, Stacy B and Perry, William R G and Sridhar, Amaanti and Szarka, Lawrence A and Busby-Whitehead, Jan and Hamilton, Frank A},
  title = {Comparative Effectiveness of Biofeedback vs Dextranomer–Hyaluronate Injection for Fecal Incontinence: A Randomized Clinical Trial},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.09.040}
}
Kostenlos starten →